Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for <i>Helicobacter pylori</i> eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial

Published:2022-02-12 Issue:2 Volume:27 Page:
ISSN:1083-4389
Container-title:Helicobacter
language:en
Short-container-title:Helicobacter

Author:

Shao Qiao‐Qiao¹^ORCID,Yu Xue‐Chun¹,Yu Miao¹^ORCID,Ma Jing¹,Zhao Jun‐Bo¹^ORCID,Yuan Lin¹,Qi Ya‐Bin¹,Hu Ruo‐Bing¹,Wei Pei‐Ru¹,Xiao Wei¹,Lan Ling¹^ORCID,Jia Bai‐Ling¹,Zhang Lian‐Zhong²,Ding Song‐Ze¹^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology People's Hospital of Zhengzhou University and Henan Provincial People’s Hospital Zhengzhou China

2. Department of Ultrasound Imaging People's Hospital of Zhengzhou University Henan Provincial People’s Hospital Zhengzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hel.12876

Reference38 articles.

1. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection

2. Primary Antibiotic Resistance of Helicobacter pylori in China

3. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations

4. A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐lineHelicobacter pyloriinfection eradication: A randomized trial

5. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research on drug treatment and the novel signaling pathway of chronic atrophic gastritis;Biomedicine & Pharmacotherapy;2024-07

2. Safety profile of Helicobacter pylori eradication treatments: literature review and updated data of the European Registry on Helicobacter pylori management (Hp-EuReg);Expert Opinion on Drug Safety;2024-04-03

3. Application of furazolidone in Helicobacter pylori infection eradication;Journal of Digestive Diseases;2024-03

4. High‐dose dual therapy versus bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta‐analysis;Journal of Digestive Diseases;2024-03

5. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study;Journal of Gastroenterology;2023-10-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3